FDA Clears First Clinical Study of OBI-3424 in Prostate and Other Cancers

FDA Clears First Clinical Study of OBI-3424 in Prostate and Other Cancers
OBI Pharma is launching a Phase 1/2 trial in the United States to evaluate the safety and effectiveness of using OBI-3424 to treat solid cancers that are positive for the AKR1C3 enzyme. This follows the recent approval of an investigational new drug (IND) application for OBI-3424 by the U.S. Food and Drug Administrations (FDA). The trial will

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *